Journal article · 2026 · Open access

Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)

Rachael McClenahan, Laith Alamlih

Frontiers in Immunology, 17, 1908442 · Published 30 September 2026 · DOI 10.3389/fimmu.2026.1908442

Open PDFView at the publisherCite this paper

In brief

“Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)” is a 2026 journal article by Rachael McClenahan and Laith Alamlih, published in Frontiers in Immunology. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.

Citations
0
References
27
Authors
2

Abstract

Objectives: This study aims to compare cardiovascular and mortality outcomes of Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) at elevated cardiovascular risk using target trial emulation. Methods: Within TriNetX, adults with RA aged ≥50 years and ≥1 cardiovascular risk factor initiating JAKi or TNFi were compared in a new-user, active-comparator design. Improved 1:1 propensity score matching incorporated demographics, cardiovascular risk factors, comorbidities, individual conventional synthetic DMARDs, oral corticosteroids, prior non-TNF biologic exposure, and baseline inflammatory markers. The primary outcome was MACE (nonfatal myocardial infarction or nonfatal ischemic stroke); the secondary outcomes were all-cause mortality, heart failure hospitalization, and venous thromboembolism (VTE), with cataract as a prespecified negative control. Follow-up began 90 days after initiation. Cox models estimated hazard ratios, with 5-year Kaplan-Meier cumulative incidences and absolute risk differences per 1,000. Cohorts were separately matched by agent, sex, cardiovascular-risk stratum, and index era; E-values quantified sensitivity to unmeasured confounding. Results: = 0.0014; +10.4 per 1,000; E-value 1.586), whereas heart failure hospitalization (HR 1.019, 0.955-1.088) and VTE (HR 1.054, 0.961-1.156) did not differ; the negative control showed no excess (HR 0.934, 0.867-1.007). No agent showed a significant excess in MACE or mortality (mortality HR 1.052 tofacitinib, 1.213 baricitinib, and 1.090 upadacitinib); the only nominally significant agent-level finding was VTE with baricitinib (HR 1.364, 1.028-1.809; 198 events). A three-component composite including death was non-significant (HR 1.058, 0.992-1.127). No consistent effect modification was seen by sex, cardiovascular risk burden, or index year. Conclusion: JAKi initiation was not associated with excess MACE (primary outcome), heart failure hospitalization, or VTE. A modest excess in all-cause mortality was observed as a secondary outcome, with no signal for any individual agent. This association was of modest robustness (E-value 1.586) and was not reproduced in any agent-specific cohort, so residual channeling bias cannot be excluded. The null MACE result should not be read as class-wide cardiovascular safety reassurance nor the mortality signal as an established causal effect.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

McClenahan, R., & Alamlih, L. (2026). Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA). Frontiers in Immunology, 17, 1908442. https://doi.org/10.3389/fimmu.2026.1908442

MLA 9

McClenahan, Rachael, and Laith Alamlih. “Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA).” Frontiers in Immunology, vol. 17, 2026, p. 1908442. https://doi.org/10.3389/fimmu.2026.1908442.

Chicago

McClenahan, Rachael and Laith Alamlih. 2026. “Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA).” Frontiers in Immunology 17: 1908442. https://doi.org/10.3389/fimmu.2026.1908442.

Harvard

McClenahan, R. and Alamlih, L. (2026) ‘Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)’, Frontiers in Immunology, 17, p. 1908442. doi:10.3389/fimmu.2026.1908442.

IEEE

R. McClenahan and L. Alamlih, “Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA),” Frontiers in Immunology, vol. 17, p. 1908442, 2026, doi: 10.3389/fimmu.2026.1908442.

BibTeX

@article{mcclenahan2026cardiovascular,
  title     = {{Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)}},
  author    = {McClenahan, Rachael and Alamlih, Laith},
  journal   = {Frontiers in Immunology},
  year      = {2026},
  volume    = {17},
  pages     = {1908442},
  doi       = {10.3389/fimmu.2026.1908442},
  url       = {https://doi.org/10.3389/fimmu.2026.1908442}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • tumor necrosis factor inhibitors
  • cardiovascular risk
  • major adverse cardiovascular events
  • mortality
  • heart failure hospitalization
  • venous thromboembolism

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

McClenahan, R., & Alamlih, L. (2026). Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA). Frontiers in Immunology, 17, 1908442. https://doi.org/10.3389/fimmu.2026.1908442

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.

Who wrote this paper?

Rachael McClenahan, Laith Alamlih.

What is the DOI of this paper?

10.3389/fimmu.2026.1908442, permanently at https://doi.org/10.3389/fimmu.2026.1908442. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.